WO2006073457A8 - Bioactive compounds and methods of uses thereof - Google Patents
Bioactive compounds and methods of uses thereofInfo
- Publication number
- WO2006073457A8 WO2006073457A8 PCT/US2005/015280 US2005015280W WO2006073457A8 WO 2006073457 A8 WO2006073457 A8 WO 2006073457A8 US 2005015280 W US2005015280 W US 2005015280W WO 2006073457 A8 WO2006073457 A8 WO 2006073457A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- bioactive compounds
- compounds
- present
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002565242A CA2565242A1 (en) | 2004-04-30 | 2005-05-02 | Bioactive compounds and methods of uses thereof |
EP05856683A EP1744744A4 (en) | 2004-04-30 | 2005-05-02 | Bioactive compounds and methods of uses thereof |
AU2005323436A AU2005323436A1 (en) | 2004-04-30 | 2005-05-02 | Bioactive compounds and methods of uses thereof |
JP2007511090A JP2007535575A (en) | 2004-04-30 | 2005-05-02 | Biologically active compounds and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56734004P | 2004-04-30 | 2004-04-30 | |
US60/567,340 | 2004-04-30 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006073457A2 WO2006073457A2 (en) | 2006-07-13 |
WO2006073457A3 WO2006073457A3 (en) | 2007-02-01 |
WO2006073457A8 true WO2006073457A8 (en) | 2007-06-21 |
Family
ID=36647911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/015280 WO2006073457A2 (en) | 2004-04-30 | 2005-05-02 | Bioactive compounds and methods of uses thereof |
Country Status (6)
Country | Link |
---|---|
US (1) | US7351739B2 (en) |
EP (1) | EP1744744A4 (en) |
JP (1) | JP2007535575A (en) |
AU (1) | AU2005323436A1 (en) |
CA (1) | CA2565242A1 (en) |
WO (1) | WO2006073457A2 (en) |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2809302T3 (en) | 2004-01-22 | 2021-03-03 | Univ Miami | Coenzyme Q10 formulations to treat solid tumors by intravenous administration |
US7351739B2 (en) | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
EP1841397A4 (en) * | 2004-12-24 | 2010-01-27 | Dolphst Pty Ltd | Formulations and treatments for trichology |
NZ590209A (en) * | 2004-12-24 | 2012-09-28 | Dolphst Pty Ltd | Formulations and treatments for well-being comprising methylsulfonylmethane, a phytosterol, an extract from polygonum multiflorum and colostrum |
US8216801B2 (en) * | 2005-02-25 | 2012-07-10 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), The Volcani Center | Methods for treating inflammatory disorders |
EP1861109A2 (en) * | 2005-03-09 | 2007-12-05 | Cardax Pharmaceuticals, Inc. | Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders |
AU2006245071A1 (en) * | 2005-05-06 | 2006-11-16 | Amino Up Chemical Co., Ltd. | Health food and pharmaceutical composition for amelioration of disease induced by metabolic disorder in cartilage |
WO2007033083A2 (en) | 2005-09-12 | 2007-03-22 | Abela Pharmaceuticals, Inc. | Systems for removing dimethyl sulfoxide (dmso) or related compounds, or odors associated with same |
WO2007033180A1 (en) * | 2005-09-12 | 2007-03-22 | Abela Pharmaceuticals, Inc. | Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds |
US8480797B2 (en) | 2005-09-12 | 2013-07-09 | Abela Pharmaceuticals, Inc. | Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors |
US9427419B2 (en) * | 2005-09-12 | 2016-08-30 | Abela Pharmaceuticals, Inc. | Compositions comprising dimethyl sulfoxide (DMSO) |
EP1931364B1 (en) * | 2005-10-06 | 2010-07-21 | Nestec S.A. | Probiotic enterococci for improved immunity |
US20070082071A1 (en) * | 2005-10-07 | 2007-04-12 | Willimann John A | Composition for controlling the respiratory effects of inhaled pollutants & allergens |
US20070243268A1 (en) * | 2005-11-07 | 2007-10-18 | Jaffe Russell M | Compositions for regulating intestinal disorders and methods of use thereof |
US20070112589A1 (en) * | 2005-11-17 | 2007-05-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | User interface for providing assistance related to health |
US8468029B2 (en) * | 2005-11-17 | 2013-06-18 | The Invention Science Fund I, Llc | Subscriptions for assistance related to health |
US8532938B2 (en) * | 2005-11-17 | 2013-09-10 | The Invention Science Fund I, Llc | Testing-dependent administration of a nutraceutical |
US20070119928A1 (en) * | 2005-11-17 | 2007-05-31 | Jung Edward K | Generating a nutraceutical request from an inventory |
US20070112592A1 (en) * | 2005-11-17 | 2007-05-17 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Payments in providing assistance related to health |
US10042980B2 (en) * | 2005-11-17 | 2018-08-07 | Gearbox Llc | Providing assistance related to health |
US7827042B2 (en) * | 2005-11-30 | 2010-11-02 | The Invention Science Fund I, Inc | Methods and systems related to transmission of nutraceutical associated information |
US20070124219A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized nutraceutical selection and packaging |
US8068991B2 (en) * | 2005-11-30 | 2011-11-29 | The Invention Science Fund I, Llc | Systems and methods for transmitting pathogen related information and responding |
US20080004909A1 (en) * | 2005-11-30 | 2008-01-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems related to nutraceuticals |
US20080193919A1 (en) * | 2005-11-30 | 2008-08-14 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems and methods for receiving pathogen related information and responding |
US8297028B2 (en) * | 2006-06-14 | 2012-10-30 | The Invention Science Fund I, Llc | Individualized pharmaceutical selection and packaging |
US7927787B2 (en) * | 2006-06-28 | 2011-04-19 | The Invention Science Fund I, Llc | Methods and systems for analysis of nutraceutical associated components |
US20080082272A1 (en) * | 2005-11-30 | 2008-04-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems and methods related to nutraceuticals |
US8340944B2 (en) * | 2005-11-30 | 2012-12-25 | The Invention Science Fund I, Llc | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
US10296720B2 (en) * | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
US7974856B2 (en) * | 2005-11-30 | 2011-07-05 | The Invention Science Fund I, Llc | Computational systems and methods related to nutraceuticals |
US20070124175A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware. | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
US8000981B2 (en) * | 2005-11-30 | 2011-08-16 | The Invention Science Fund I, Llc | Methods and systems related to receiving nutraceutical associated information |
US20070299693A1 (en) * | 2006-06-23 | 2007-12-27 | Searete Llc, A Limited Liability Corporation | Customized visual marking for medication labeling |
US7897800B2 (en) * | 2006-02-03 | 2011-03-01 | Jr Chem, Llc | Chemical compositions and methods of making them |
US20090226508A1 (en) * | 2006-03-15 | 2009-09-10 | Eaton John W | Methods And Materials For Immunization Against Cancer |
US20070298013A1 (en) * | 2006-06-23 | 2007-12-27 | Altman Jay A | Animal Nutritional Supplement and Method |
US20080086338A1 (en) * | 2006-06-23 | 2008-04-10 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Customized visual marking for medication labeling |
US20070299695A1 (en) * | 2006-06-23 | 2007-12-27 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Customized visual marking for medication labeling |
US20080086339A1 (en) * | 2006-06-23 | 2008-04-10 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Customized visual marking for medication labeling |
US20080031869A1 (en) * | 2006-08-02 | 2008-02-07 | Fontaine Juliette S | Pain relief composition |
CN1994293A (en) * | 2006-08-18 | 2007-07-11 | 上海交通大学医学院附属瑞金医院 | Application of oridonin in medicine preparation |
WO2008062466A2 (en) * | 2006-10-13 | 2008-05-29 | Reliance Life Sciences Pvt. Ltd. | Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer |
EP1913821A1 (en) | 2006-10-20 | 2008-04-23 | Kraft Foods R & D, Inc. Zweigniederlassung München | Polyphenol-rich extract from plant material |
WO2008097530A1 (en) * | 2007-02-05 | 2008-08-14 | Biophile Corporation, Ltd | Increased effectiveness of allylamine drug compounds |
US20080213440A1 (en) * | 2007-03-01 | 2008-09-04 | Cadbury Adams Usa Llc | Non-Aldehyde Cinnamon Flavor and Delivery Systems Therefor |
US20080227747A1 (en) * | 2007-03-15 | 2008-09-18 | Tabbiner Philip | Composition and methods for treating or preventing degenerative joint and cardiovascular conditions |
JP4384717B2 (en) * | 2007-03-19 | 2009-12-16 | 裕三 土田 | Antiviral agent |
US7629293B2 (en) * | 2007-04-12 | 2009-12-08 | National Defense University | Manufacturing method of bamboo charcoal supporting silver and products thereof |
WO2008130752A2 (en) | 2007-04-19 | 2008-10-30 | Mary Kay Inc. | Magnolia extract containing compositions |
US8877266B2 (en) | 2007-05-02 | 2014-11-04 | Tom's Of Maine, Inc. | Supercritical CO2 liquorice extract anti-microbial and anti-inflammatory isolates and products made there from |
US8236360B2 (en) * | 2007-05-02 | 2012-08-07 | Tom's Of Maine, Inc. | Supercritical CO2 liquorice extract and products made there from |
US20080274063A1 (en) * | 2007-05-02 | 2008-11-06 | Chantal Bergeron | Supercritical CO2 liquorice extract anti-microbial and anti-inflammatory isolates and products made there from |
US7836851B2 (en) * | 2007-05-23 | 2010-11-23 | Anthony Gergely | Formula and method for treating water in fish tanks |
WO2008147563A1 (en) * | 2007-05-25 | 2008-12-04 | The Trustees Of The University Of Pennsylvania | Flaxseed lignan complex, methods of using and compositions thereof |
US10045951B2 (en) | 2007-05-25 | 2018-08-14 | The Trustees Of The University Of Pennsylvania | Flaxseed lignan complex and its use thereof |
US20080299187A1 (en) * | 2007-06-01 | 2008-12-04 | Joar Opheim | Substances for Reducing Occurence of Major Cardiac Events in Humans |
US20100119600A1 (en) | 2007-06-01 | 2010-05-13 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
US20090004326A1 (en) * | 2007-06-29 | 2009-01-01 | Randy Andrews | Beverage Additive and Method of Making the Same |
US8637094B2 (en) * | 2007-07-18 | 2014-01-28 | Iraj E. Kiani | Composition and method for treating viral conditions |
US7700137B1 (en) | 2007-07-18 | 2010-04-20 | Kiani Iraj E | Anti-viral compositions and method |
US7850998B2 (en) * | 2007-07-18 | 2010-12-14 | Kiani Iraj E | Method of treating viral conditions |
US20090062231A1 (en) * | 2007-08-31 | 2009-03-05 | O'mara Ann Marie | Appetite Suppressant Composition and Method of Appetite Suppression |
US20090087525A1 (en) * | 2007-09-28 | 2009-04-02 | Ogushi Kinsen | Manufacturing of polysaccharide based nutritional supplement |
EP2214518A4 (en) * | 2007-10-19 | 2011-06-29 | Joel D Pardee | Metabolic enhancement therapy |
US20090123610A1 (en) * | 2007-11-13 | 2009-05-14 | Mullin Keith Alan | Saleable cognitive performance snack food items and methods of preparing, packaging and using same |
AU2009233785B2 (en) | 2008-04-11 | 2015-08-20 | Berg Llc | Methods and use of inducing apoptosis in cancer cells |
BRPI0911790A2 (en) * | 2008-04-16 | 2015-10-06 | Imagilin Technology Llc | effects of probiotics on human health and animals on environmental or biological changes |
US8455024B2 (en) * | 2008-10-16 | 2013-06-04 | Visalus Holdings, Llc | Appetite suppressant composition |
BRPI0921494A2 (en) | 2008-11-03 | 2018-10-30 | Prad Reasearch And Development Ltd | method of planning a underground forming sampling operation, method of controlling a underground forming sampling operation, method of controlling a drilling operation for an underground formation, and method of sampling during the drilling operation. |
US20110238602A1 (en) * | 2008-11-13 | 2011-09-29 | Azouri Ilan Ovadia | Method for enhanced marketing of vibration medicine products and coaching therefrom |
EP2228411A1 (en) * | 2009-02-21 | 2010-09-15 | Jess Edward Rugeris | Food grade colouring agent |
KR20180056816A (en) | 2009-05-11 | 2018-05-29 | 베르그 엘엘씨 | Methods for treatment of disease using an epimetabolic shifter (coenzyme q10) |
US20110015154A1 (en) * | 2009-07-20 | 2011-01-20 | Kellermann Gottfried H | Supporting acetylcholine function |
WO2011034591A1 (en) * | 2009-09-17 | 2011-03-24 | New York University | Methods of blocking ultraviolet radiation and promoting skin growth using terpenes and terpenoids |
US20110098265A1 (en) * | 2009-10-28 | 2011-04-28 | Neuroscience, Inc. | Methods for reducing cravings and impulses associated with addictive and compulsive behaviors |
EP2493315B1 (en) | 2009-10-30 | 2018-03-28 | Abela Pharmaceuticals, Inc. | Dimethyl sulfoxide (dmso) or dmso and methylsulfonylmethane (msm) formulations to treat infectious diseases |
NZ600145A (en) | 2009-10-30 | 2013-12-20 | Biogenic Innovations Llc | Use of methylsulfonylmethane (msm) to modulate microbial activity |
US8470880B2 (en) | 2009-12-15 | 2013-06-25 | Mcneil-Ppc, Inc. | Methods of reducing hair loss and/or facilitating hair growth and/or regrowth |
US8470833B2 (en) * | 2009-12-15 | 2013-06-25 | Mcneil-Ppc, Inc. | Hair growth and/or regrowth compositions |
TWI413525B (en) * | 2010-01-22 | 2013-11-01 | Univ Nat Taiwan Normal | Use of medical composition for preparing drug of inhibiting the growth of cancer stem cell |
US20110195130A1 (en) * | 2010-02-09 | 2011-08-11 | Sanford Siegal | Edible compositions |
BR112012024214A2 (en) * | 2010-03-24 | 2019-09-24 | Nestec Sa | method for improving the palatability of edible compositions. |
US20150064263A1 (en) * | 2010-05-25 | 2015-03-05 | David Kossor | Compositions and methods for reduction of mercury toxicity |
US20110301099A1 (en) * | 2010-06-04 | 2011-12-08 | Madalene Choon Ying Heng | Method for enhancing penetration of lipid insoluble medicaments through cell membranes using small S-Allyl-containing molecules with phospholipid permeability as carrier molecules |
US8574639B2 (en) * | 2010-08-17 | 2013-11-05 | ILHWA Co., Ltd. | Fermented ginseng concentrate having IH-901 |
US8039025B1 (en) | 2010-10-15 | 2011-10-18 | Life Plus, LLC | Methods and dosage forms for the treatment of human cancers |
US20120107300A1 (en) * | 2010-11-01 | 2012-05-03 | Jeffrey Nathan Schirripa | Cannabinoid Compositions and Methods |
TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
WO2012090194A2 (en) * | 2010-12-29 | 2012-07-05 | Abrham Galya | Compositions and methods for treating a skin disorder |
WO2012092673A1 (en) | 2011-01-08 | 2012-07-12 | Kane Penny Colleen | Bee bloom compositions, methods of extraction and uses thereof |
RU2468791C2 (en) * | 2011-02-24 | 2012-12-10 | Общество с ограниченной ответственностью "ДИНАМИК ДЕВЕЛОПМЕНТ ЛАБОРАТОРИЗ" | Composition, possessing adaptogenic, general tonic and working capacity-increasing acyion |
WO2012129047A1 (en) * | 2011-03-18 | 2012-09-27 | Albert Einstein College Of Medicine Of Yeshiva University | Oral administration of melanin for protection against radiation |
US20120269867A1 (en) | 2011-04-04 | 2012-10-25 | Jimenez Joaquin J | Methods of treating central nervous system tumors |
WO2012142511A2 (en) | 2011-04-15 | 2012-10-18 | Md Matrix Health Llc Dba Md Matrix Health Inc | Orthomolecular compositions and their use in stabilizing the extracellular matrix |
WO2012170467A1 (en) | 2011-06-07 | 2012-12-13 | New York University | Compositions and methods for restoring the stratum corneum and treating dermatological diseases |
CN102584780B (en) * | 2012-01-16 | 2014-05-28 | 新乡医学院 | Glaucocalyxin derivative as well as preparing method and application thereof |
US20140234515A1 (en) * | 2013-02-15 | 2014-08-21 | William Cain | Nutraceutical formulation |
CA2911620C (en) | 2013-04-05 | 2022-03-08 | The Board Of Regents Of The University Of Texas System | Oridonin analogs, compositions, and methods related thereto |
SG11201508272YA (en) | 2013-04-08 | 2015-11-27 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
CN103230388B (en) * | 2013-05-17 | 2014-09-17 | 中国科学院昆明植物研究所 | Application of isodon henryi as Wnt signal path inhibitor and anti-cancer drug |
US9955715B1 (en) | 2013-06-12 | 2018-05-01 | Biosilo Foods, Inc | Manufacture of vegetable-based cluster-type snack-food product with low sugar binder |
SG10201907816RA (en) | 2013-09-04 | 2019-09-27 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme q10 |
CA2931255A1 (en) * | 2013-11-27 | 2015-06-04 | Research Foundation Of The City University Of New York | Activity enhancing curcumin compositions and methods of use |
CN103919764B (en) * | 2014-04-22 | 2017-12-22 | 中国药科大学 | New application of the Oridonin derivative in terms of antituberculotic is prepared |
CN105092767A (en) * | 2014-05-21 | 2015-11-25 | 天津市汉康医药生物技术有限公司 | Method for detecting quality of intermediate of semisynthesis medicine |
KR102382930B1 (en) * | 2014-08-25 | 2022-04-04 | 아나타라 라이프사이언시즈 리미티드 | Anti-diarrhea formulation which avoids antimicrobial resistance |
US20160331709A1 (en) * | 2015-05-13 | 2016-11-17 | Wow Llc??? | Balancing an Unbalanced Sympathetic Nervous System |
KR101589466B1 (en) | 2015-05-21 | 2016-02-01 | 주식회사 쎌바이오텍 | Use of bifidobacterium longum cbt bg7 strain for promoting growth and nutraceutical composition for promoting growth comprising the same |
US20180243327A1 (en) * | 2015-09-01 | 2018-08-30 | The Trustees Of The University Of Pennsylvania | USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION DAMAGE |
US10828251B1 (en) | 2017-01-14 | 2020-11-10 | Biolyte Laboratories, Llc | Homeopathic formulations |
US10617634B1 (en) | 2017-03-10 | 2020-04-14 | Biolyte Laboratories, Llc | Topical homeopathic formulations for menstrual cramps |
CN110151749B (en) * | 2018-02-13 | 2022-04-19 | 中国科学技术大学 | Application of oridonin in preparing medicine for preventing or treating NLRP3 inflammation body related diseases |
CN108693295B (en) * | 2018-04-20 | 2020-08-11 | 国药集团德众(佛山)药业有限公司 | Identification method of artemisia pigweed essential oil |
WO2020018888A1 (en) | 2018-07-20 | 2020-01-23 | The Board Of Regents Of The University Of Oklahoma | Antimicrobial peptides and methods of use |
US20200345805A1 (en) * | 2019-04-22 | 2020-11-05 | Allegro Ophthalmics, Llc | Compositions and methods useable for treatment of dry eye |
CN110243991A (en) * | 2019-06-13 | 2019-09-17 | 广西中医药大学 | A kind of quality determining method of precious jade remedies rape medicinal material |
US11744866B2 (en) | 2020-03-18 | 2023-09-05 | Sabine Hazan | Methods of preventing and treating COVID-19 infection with probiotics |
US11253534B2 (en) | 2020-03-23 | 2022-02-22 | Sabine Hazan | Method of preventing COVID-19 infection |
US11278520B2 (en) | 2020-03-31 | 2022-03-22 | Sabine Hazan | Method of preventing COVID-19 infection |
WO2022011305A2 (en) * | 2020-07-09 | 2022-01-13 | Beyond Barriers Therapeutics, Inc. | Intranasal administration of an antioxidant compound for treating coronavirus infection |
WO2022034515A1 (en) * | 2020-08-13 | 2022-02-17 | Shrinivasan Sowmmya | Solubilized piperine composition and it's process |
CN112402410B (en) * | 2020-12-21 | 2021-09-17 | 郑州大学 | Application of oridonin in preparing medicine for treating hyperuricemia and anti-gout |
WO2023287620A1 (en) * | 2021-07-13 | 2023-01-19 | Michael Rabinoff | Methods for treating coronavirus infection |
WO2023064399A1 (en) * | 2021-10-12 | 2023-04-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Prenatal supplement |
CN114515302B (en) * | 2022-01-04 | 2023-07-14 | 广州白云山和记黄埔中药有限公司 | Use of rabdosia lophanthide extract as sole active ingredient in preparation of medicament for preventing and/or treating ulcerative colitis |
CN114814065B (en) * | 2022-04-12 | 2023-12-01 | 上海交通大学 | VOC marker in saliva of helicobacter pylori and application of VOC marker in preparation of diagnostic reagent |
WO2023239171A1 (en) * | 2022-06-08 | 2023-12-14 | 주식회사 엑티브온 | Novel compound and use thereof |
CN116420737B (en) * | 2023-06-08 | 2023-10-10 | 山东京青农业科技有限公司 | Bacillus subtilis water dispersible granule and preparation method and application thereof |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536123A (en) * | 1968-05-14 | 1970-10-27 | Izumi Automotive Ind Co | Method of making internal combustion engine cylinder made of an aluminum alloy enriched with a wear-resistant component on the inside surface |
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4658019A (en) | 1979-04-26 | 1987-04-14 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells |
JPS57179185A (en) * | 1981-04-28 | 1982-11-04 | Taiho Yakuhin Kogyo Kk | Rubescensin c |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5851526A (en) | 1985-04-19 | 1998-12-22 | Ludwig Institute For Cancer Research | Methods of treating colon cancer utilizing tumor-specific antibodies |
US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
DE3631229A1 (en) | 1986-09-13 | 1988-03-24 | Basf Ag | MONOCLONAL ANTIBODIES AGAINST HUMAN TUMORNESCROSE FACTOR (TNF) AND THEIR USE |
US5306620A (en) | 1987-07-08 | 1994-04-26 | The Scripps Research Institute | Antibodies that bind to a ligand-induced binding site on integrin and induce integrin activation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5149780A (en) | 1988-10-03 | 1992-09-22 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
CA2000048A1 (en) | 1988-10-03 | 1990-04-03 | Edward F. Plow | Peptides and antibodies that inhibit integrin-ligand bindin g |
US5360716A (en) | 1988-10-24 | 1994-11-01 | Otsuka Pharmaceutical Co., Ltd. | Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α |
US5223395A (en) | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
US5147638A (en) | 1988-12-30 | 1992-09-15 | Oklahoma Medical Research Foundation | Inhibition of tumor growth by blockade of the protein C system |
IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
US5498694A (en) | 1989-05-25 | 1996-03-12 | La Jolla Cancer Research Foundation | Peptides of the cytoplasmic domain of integrin |
US5959087A (en) | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
US5644034A (en) | 1989-08-07 | 1997-07-01 | Peptide Technology Ltd. | Tumour necrosis factor binding ligands |
EP0939121B2 (en) | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TNF-binding proteins |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5196511A (en) | 1989-12-01 | 1993-03-23 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
US5262520A (en) | 1989-12-01 | 1993-11-16 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
US5136021A (en) | 1990-02-27 | 1992-08-04 | Health Research, Inc. | TNF-inhibitory protein and a method of production |
DE4006269A1 (en) | 1990-02-28 | 1991-08-29 | Max Planck Gesellschaft | Antibody which binds to tumour necrosis factor receptors |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
EP0456950A1 (en) * | 1990-05-16 | 1991-11-21 | CONTRAVES ITALIANA S.p.A. | Actuator for restraint/release (R/R) devices, particularly for space applications |
US5830678A (en) | 1990-10-30 | 1998-11-03 | Fred Hutchinson Cancer Research Center | Method for identifying a target peptide that modulates the binding of epinectin ligand to integrin receptors |
US5994510A (en) | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
GB9028123D0 (en) | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
JPH06506195A (en) | 1991-01-14 | 1994-07-14 | ニューヨーク ユニバシテイ | Cytokine-induced protein, TSG-14, DNA encoding therefor and uses thereof |
EP0495376B1 (en) | 1991-01-15 | 1997-05-28 | Bayer Corporation | Cell surface receptor complimentation |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US5698195A (en) | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
US5310874A (en) | 1991-05-03 | 1994-05-10 | The Scripps Research Institute | Integrin α subunit cytoplasmic domain polypeptides and antibodies |
US5334380A (en) | 1991-09-27 | 1994-08-02 | Board Of Regents, The University Of Texas System | Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension |
US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
DE4135070C1 (en) | 1991-10-24 | 1993-05-19 | Institut Fuer Rundfunktechnik Gmbh, 8000 Muenchen, De | |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
IL104684A0 (en) | 1992-02-14 | 1993-06-10 | Bristol Myers Squibb Co | The cd40cr receptor and ligands therefor |
EP0633945B1 (en) | 1992-04-03 | 1998-12-30 | Genentech, Inc. | ANTIBODIES TO ALPHAvBETA3 INTEGRIN |
US5478725A (en) | 1992-06-12 | 1995-12-26 | University Of Pennsylvania | αv β3 integrin as a predictor of endometriosis |
ATE155043T1 (en) | 1992-10-08 | 1997-07-15 | Kennedy Inst Of Rheumatology | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES |
US5705481A (en) | 1992-11-06 | 1998-01-06 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Cyclopeptides |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
DE4310643A1 (en) | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Cyclic adhesion inhibitors |
IT1273790B (en) | 1994-02-18 | 1997-07-10 | Guidotti & C Spa Labor | DIAZOTATED HETEROCYCLIC DERIVATIVES WITH ACTIVITIES TO THE ANTAGONIST |
US5523209A (en) | 1994-03-14 | 1996-06-04 | The Scripps Research Institute | Methods for identifying inhibitors of integrin activation |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US5770565A (en) | 1994-04-13 | 1998-06-23 | La Jolla Cancer Research Center | Peptides for reducing or inhibiting bone resorption |
DE4415310A1 (en) | 1994-04-30 | 1995-11-02 | Merck Patent Gmbh | Cyclopeptides |
NZ288997A (en) | 1994-06-24 | 1999-01-28 | Immunex Corp | Controlled release pharmaceutical formulation comprising polypeptide encapsulated in alginate |
IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
EP0719859B1 (en) | 1994-12-20 | 2003-07-02 | MERCK PATENT GmbH | Anti-alpha V-integrin monoclonal antibody |
US5610185A (en) * | 1995-02-17 | 1997-03-11 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein cross-linking compounds |
US5780426A (en) | 1995-06-07 | 1998-07-14 | Ixsys, Incorporated | Fivemer cyclic peptide inhibitors of diseases involving αv β3 |
US5767071A (en) | 1995-06-07 | 1998-06-16 | Ixsys Incorporated | Sevenmer cyclic peptide inhibitors of diseases involving αv β3 |
US5817750A (en) | 1995-08-28 | 1998-10-06 | La Jolla Cancer Research Foundation | Structural mimics of RGD-binding sites |
KR0177105B1 (en) * | 1995-12-18 | 1999-05-01 | 김광호 | Horizontal drive circuit |
US5817457A (en) | 1996-02-07 | 1998-10-06 | Ma Bioservices, Inc. | Methods and kits for detecting viral reverse transcriptase activity in a sample using an acidic pH or an elevated temperature |
US5955269A (en) | 1996-06-20 | 1999-09-21 | Rutgers, The State University Of New Jersey | Methods of screening foods for nutraceuticals |
US5665393A (en) | 1996-09-03 | 1997-09-09 | International Medical Research, Inc. | Herbal composition for treating prostate carcinoma |
IL129344A0 (en) | 1996-11-27 | 2000-02-17 | Du Pont Pharm Co | Novel integrin receptor antagonists |
US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
AU6702998A (en) | 1997-03-12 | 1998-09-29 | Smithkline Beecham Corporation | Anti-alphabeta3 humanized monoclonal antibodies |
US5968741A (en) | 1997-04-11 | 1999-10-19 | Cedars-Sinai Medical Center | Methods of diagnosing a medically resistant clinical subtype of ulcerative colitis |
CA2284726A1 (en) | 1997-04-11 | 1998-10-22 | G.D. Searle & Co. | Antagonistic anti-avb3 integrin antibodies |
US6171787B1 (en) | 1997-06-26 | 2001-01-09 | Abbott Laboratories | Member of the TNF family useful for treatment and diagnosis of disease |
US6096707A (en) | 1997-07-11 | 2000-08-01 | Biotie Therapies Ltd. | Integrin binding peptide and use thereof |
JP2001524481A (en) | 1997-11-26 | 2001-12-04 | デュポン ファーマシューティカルズ カンパニー | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as αVβ3 antagonists |
US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
WO2000009503A1 (en) | 1998-08-13 | 2000-02-24 | Merck & Co., Inc. | Integrin receptor antagonists |
US6160099A (en) | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
US6114517A (en) | 1998-12-10 | 2000-09-05 | Isis Pharmaceuticals Inc. | Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules |
US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
WO2001021165A1 (en) | 1999-09-21 | 2001-03-29 | Rutgers, The State University | Resveratrol analogs for prevention of disease |
EP1214040A4 (en) | 1999-09-21 | 2004-06-23 | Univ Rutgers | Extracts of orange peel for prevention and treatment of cancer |
ATE304367T1 (en) | 2000-06-13 | 2005-09-15 | Univ Rutgers | ANTI-CARCINOGENIC ACTIVITY OF HYDROXYLATED CHALCONIC COMPOUNDS ISOLATED FROM LICORICE ROOT |
AU2002217832A1 (en) | 2000-11-15 | 2002-05-27 | Rutgers, The State University Of New Jersey | Black tea extract for prevention of disease |
US20030035851A1 (en) | 2001-02-08 | 2003-02-20 | Sophie Chen | Anti-cancer agents and method of use thereof |
EP1381378A4 (en) | 2001-02-21 | 2004-07-28 | Univ Rutgers | Compositions and methods for cancer prevention and treatment derived from inula britannica |
WO2002070007A1 (en) | 2001-03-02 | 2002-09-12 | Medimmune, Inc. | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
CA2468544A1 (en) * | 2001-12-10 | 2003-06-19 | Amgen Inc. | Vanilloid receptor ligands |
US7351739B2 (en) | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
-
2005
- 2005-04-29 US US11/118,915 patent/US7351739B2/en not_active Expired - Fee Related
- 2005-05-02 EP EP05856683A patent/EP1744744A4/en not_active Withdrawn
- 2005-05-02 WO PCT/US2005/015280 patent/WO2006073457A2/en active Application Filing
- 2005-05-02 JP JP2007511090A patent/JP2007535575A/en not_active Withdrawn
- 2005-05-02 CA CA002565242A patent/CA2565242A1/en not_active Abandoned
- 2005-05-02 AU AU2005323436A patent/AU2005323436A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1744744A4 (en) | 2010-08-25 |
CA2565242A1 (en) | 2006-07-13 |
US20060052438A1 (en) | 2006-03-09 |
WO2006073457A3 (en) | 2007-02-01 |
WO2006073457A2 (en) | 2006-07-13 |
AU2005323436A1 (en) | 2006-07-13 |
JP2007535575A (en) | 2007-12-06 |
EP1744744A2 (en) | 2007-01-24 |
US7351739B2 (en) | 2008-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006073457A3 (en) | Bioactive compounds and methods of uses thereof | |
WO2007120980A3 (en) | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases | |
WO2007011962A3 (en) | Treatment of cancer | |
WO2006107451A3 (en) | Honokiol derivatives for the treatment of proliferative disorders | |
WO2006133426A3 (en) | Compositions and methods for inhibition of the jak pathway | |
WO2008030883A3 (en) | Treatment of cancer | |
WO2007109279A3 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
MX2007002398A (en) | New pharmaceutical compositions for the treatment of cancer. | |
WO2007016538A3 (en) | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity | |
PL381247A1 (en) | Heterocyclical condensed derivative, the medical composition containing it as well as its treatment application | |
WO2006113919A3 (en) | Aryl alkyl acid derivatives for and use thereof | |
WO2008057512A3 (en) | Imidazopyrazines as protein kinase inhibitors | |
WO2004080391A3 (en) | Novel antibacterial agents | |
WO2005111039A3 (en) | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | |
IL188475A0 (en) | Pyrido [2,3-d]pyrimidine-2,4-diamine compounds as ptpib inhibitors | |
WO2007098507A3 (en) | Compositions and methods for inhibition of the jak pathway | |
WO2007067506A3 (en) | 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors | |
WO2006024018A3 (en) | Compositions for treating nociceptive pain | |
WO2006125539A3 (en) | Combination therapy comprising diaryl ureas for treating diseases | |
WO2007120333A3 (en) | Tetracyclic kinase inhibitors | |
WO2007106436A3 (en) | Photoactive compounds and compositions and uses thereof | |
WO2007066336A3 (en) | Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof | |
WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
WO2007056625A3 (en) | Thienopyridine b-raf kinase inhibitors | |
WO2005085188A3 (en) | Compounds and methods for anti-tumor therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007511090 Country of ref document: JP Ref document number: 2565242 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005323436 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005856683 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005323436 Country of ref document: AU Date of ref document: 20050502 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005323436 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005856683 Country of ref document: EP |